| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC18A2 |
| Uniprot No | Q05940 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 53-151 aa |
| 活性数据 | HEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGL |
| 分子量 | 36.63 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC18A2(VMAT2)蛋白的3篇示例参考文献(注：文献为虚构，仅供格式参考，建议通过PubMed等平台获取真实文献)：
---
1. **文献名称**: "Expression and Functional Characterization of Recombinant Human VMAT2 in Mammalian Cells"
**作者**: Lee, J. et al.
**摘要**: 本文通过哺乳动物HEK293细胞系统成功表达重组人SLC18A2蛋白，利用亲和层析纯化获得高纯度蛋白，并验证其单胺转运活性及药物(如丁苯那嗪)抑制效应。
2. **文献名称**: "Cryo-EM Structure of Human VMAT2 Reveals Substrate Transport Mechanism"
**作者**: Zhang, Y. et al.
**摘要**: 通过冷冻电镜解析了重组人SLC18A2蛋白的3.8Å高分辨率结构，揭示了其底物识别及质子梯度驱动转运的分子机制，为靶向药物设计提供结构基础。
3. **文献名称**: "Development of a Novel Assay for VMAT2 Activity Using Recombinant Protein in Lipid Nanodiscs"
**作者**: Torres, R. et al.
**摘要**: 研究将重组SLC18A2蛋白嵌入脂质纳米盘中构建体外功能体系，开发出基于荧光染料的单胺转运动态检测方法，用于高通量筛选神经退行性疾病治疗药物。
---
建议通过 **PubMed** 或 **Web of Science** 搜索关键词“recombinant SLC18A2/VMAT2”获取真实文献。例如，近年SLC18A2结构研究可参考Nature (2020)等期刊。
Recombinant human SLC18A2 protein, also known as vesicular monoamine transporter 2 (VMAT2), is a critical transmembrane protein responsible for regulating the storage and release of monoamine neurotransmitters. Belonging to the solute carrier family 18. SLC18A2 is primarily expressed in the brain, adrenal glands, and neuroendocrine cells. It functions by transporting monoamines—such as dopamine, serotonin, norepinephrine, and histamine—from the cytoplasm into synaptic vesicles, a process dependent on proton gradient energy. This vesicular sequestration ensures neurotransmitter availability for regulated exocytosis and prevents cytoplasmic accumulation, which could lead to oxidative damage.
The recombinant form of SLC18A2 is engineered using heterologous expression systems (e.g., mammalian or insect cells) for functional and structural studies. It serves as a key target for neuropharmacology research, particularly in disorders like Parkinson’s disease, depression, and schizophrenia. VMAT2 inhibitors, such as tetrabenazine and valbenazine, are clinically used to manage hyperkinetic movement disorders (e.g., Huntington’s disease) by modulating monoamine neurotransmission. Additionally, polymorphisms in SLC18A2 have been linked to neuropsychiatric conditions, driving interest in its role as a biomarker or therapeutic candidate. Researchers employ recombinant SLC18A2 to study transport mechanisms, drug interactions, and pathological mutations, providing insights into monoaminergic signaling dysregulation. Its biochemical characterization continues to advance drug discovery for neurological and psychiatric diseases.
×
